# A Phase II Clinical Trial on the Efficacy and Safety of TQC3721 Inhalation Powder

> **NCT07252908** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 195 (estimated)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** TQC3721 inhalation powder
- **DRUG:** Placebo for TQC3721 inhalation powder

## Key facts

- **NCT ID:** NCT07252908
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-12-22
- **Primary completion:** 2026-05
- **Final completion:** 2026-06
- **Target enrollment:** 195 (ESTIMATED)
- **Last updated:** 2026-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07252908

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07252908, "A Phase II Clinical Trial on the Efficacy and Safety of TQC3721 Inhalation Powder". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07252908. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*